Ashland announces Klucel™ xtend HPC matrix former for extended-release tablets

Wilmington, Del., Oct. 3, 2022 - Ashland is introducing Klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver unsurpassed process versatility and release profile efficiency. 
Until now, there were limited options for managing the release profile of formulations, especially high dose, controlled release formulations. Ashland’s step change klucel™ xtend HPC has been shown to match the release profile of hypromellose controlled-release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with klucel™ xtend HPC offers the possibility of smaller pills or higher dosage, if necessary. This new excipient offers unrivaled versatility across a broad range of APIs in every manufacturing process: dry granulation, wet-granulation, direct compression, and holt-melt extrusion.

Wilmington, Del., Oct. 3, 2022 - Ashland is introducing Klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver unsurpassed process versatility and release profile efficiency. 
Until now, there were limited options for managing the release profile of formulations, especially high dose, controlled release formulations. Ashland’s step change klucel™ xtend HPC has been shown to match the release profile of hypromellose controlled-release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with klucel™ xtend HPC offers the possibility of smaller pills or higher dosage, if necessary. This new excipient offers unrivaled versatility across a broad range of APIs in every manufacturing process: dry granulation, wet-granulation, direct compression, and holt-melt extrusion.